Involvement of TGF-βs/TβRs system in tumor progression of murine mammary adenocarcinomas

Breast Cancer Research and Treatment

Volumn 80, Issue 3, 2003, Pages 287-301

  Daroqui, M Cecilia ^a   Puricelli, Lydia I ^a,c   Urtreger, Alejandro J ^a   Elizalde, Patricia V ^b   Lanuza, Guillermo M ^b   Bal De Kier Joffé, Elisa ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c Instituto de Oncologia Angel H Roffo   (Argentina)

Author keywords

Metastatic capability; MMP; Murine mammary adenocarcinoma; PAI; TGF ; uPA

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL CELL; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SYNTHESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ANIMALS; CELL DIFFERENTIATION; CELL DIVISION; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; MAMMARY NEOPLASMS, ANIMAL; METALLOPROTEASES; MICE; NEOPLASM METASTASIS; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0042825473     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024910332621     Document Type: Article

References (59)

1. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000
2. Roberts AB, Sporn MB: The transforming growth factor beta. In: Sporn MB, Roberts AB (eds) Peptide Growth Factors and their Receptors. Part 1. Springer, Berlin, 1990, pp 419-472
3. Barnard JA, Lyons RM, Moses HL: The cell biology of TGF-β. Biochim Biophys Acta 1032: 79-87, 1990
4. Massagué J: The TGF-β family. Annu Rev Cell Biol 6: 597-641, 1990
5. Norgaard P, Hougaard S, Skovgaard Poulsen H, Spang-Thomsen M: Transforming growth factor beta and cancer. Cancer Treat Rev 21: 367-403, 1995
6. Massagué J: TGF-β signal transduction. Annu Rev Biochem 67: 753-791, 1998
7. Miyazono K, Yuki K, Takaku F, Wernstedt C, Kanzaki T, Heldin C-H: Latent forms of TGF-β: structure and biology. Ann NY Acad Sci 593: 51-58, 1990
8. Crawford SE, Stelmach V, Murphy-Ullrich JE: Thrombospondin-1 is a major activator of TGF-β1 in vivo. Cell 93: 1159-1170, 1998
9. Baillie R, Coombes RC, Smith J: Multiple forms of TGF-β1 in breast tissues: a biologically active forms of the small latent complex of TGF-β1. Eur J Cancer 32A(9): 1566-1573, 1996
10. Barcellos-Hoff MH, Ewan KBR: Transforming growth factor-β and breast cancer mammary gland development. Breast Cancer Res 2: 92-99, 2000
11. Wrana JL, Attisano L, Cárcamo J, Zentella A, Doody J, Laiho M, Wang XF, Massagué J: TGF signals through a heteromeric protein kinase receptor complex. Cell 71: 1003-1014, 1992
12. Kelly DL, Rizzino A: Growth regulatory factors and carcinogenesis: the roles played by transforming growth factor beta, its receptors and signaling pathways. Anticancer Res 19(6A): 4791-4807, 1999
13. Dumont N, Arteaga CL: Transforming growth factor-β and breast cancer. Tumor promoting effects of transforming growth factor-β. Breast Cancer Res 2: 125-132, 2000
14. Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89(17): 1260-1270, 1997
15. Birkedal-Hansen H: Proteolytic remodeling of extracellular matrix. Curr Opt Cell Biol 7: 728-735, 1995
16. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18: 1135-1149, 2000
17. Danø K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139-266, 1985
18. Moller LB: Structure and function of the urokinase receptor. Blood Coag Fibrin 4: 293-303, 1993
19. Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Graeff H: Urokinase type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69-78, 1990
20. Mayer M: Biochemical and biological aspects of the plasminogen activator system. Clin Biochem 23: 197-211, 1990
21. Andreasen PA, Kjoller L, Christensen L, Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72(1): 1-22, 1997
22. Wells JM, Strickland S: Regulated localization confers multiple functions on the protease urokinase plasminogen activator. J Cell Phys 171: 217-225, 1997
23. Werb Z: ECM and cell surface proteolysis: regulating cellular ecology. Cell 91: 439-442, 1997
24. Overall CM, Wrana JL, Sodek J: Independent regulation of collagenase, 72 kDa progelatinase and metalloendoproteinase inhibitor expression in human fibroblasts by TGF-β. J Biol Chem 264(3): 1860-1869, 1989
25. Agarwal C, Hembree JR, Rorke EA, Eckert RL: TGF-β1 regulation of metalloproteinase production in cultured human cervical epithelial cells. Cancer Res 54: 943-949, 1994
26. Farina AR, Coppa AR, Tiberio A, Tacconelli A, Turco A, Colletta G, Gulino A, Mackay AR: TGF-β1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by upregulating uPA activity. Int J Cancer 75: 721-730, 1998
27. Bal de Kier Joffé E, Puricelli L, Vidal MC, Lustig ES: Characterization of two murine mammary adenocarcinoma tumors with different metastatic ability. J Exp Clin Cancer Res 2: 151-160, 1983
28. Urtreger AJ, Ladeda VE, Puricelli LI, Rivelli A, Vidal MC, Lustig ES, Bal de Kier Joffé E: Modulation of fibronectin expression and proteolytic activity associated to the invasive and metastatic phenotype in two murine mammary tumor cell lines. Int J Oncol 11: 489-496, 1997
29. Puricelli LI, Gómez DE, Vidal MC, Eijan AM, Spinelli O, Alonso DF, Lustig ES. Bal de Kier Joffé E: Effects of host-organ environment on the in vivo and in vitro behavior of a murine mammary adenocarcinoma. Tumor Biol 15: 284-293, 1994
30. Guerra FK, Eijan AM, Puricelli LI, Alonso DF, Bal de Kier Joffé E, Kornblihtt AR, Charreau EH, Elizalde PV: Varying patterns of expression of IGFI and IGFII and theirs receptors in murine mammary adenocarcinoma of different metastasizing ability. Int J Cancer 65: 812-820, 1996
31. Colombo L, Bonaparte Y, Klein S, Stillitani D'Elia Y: Selección in vivo de una línea tumoral con alta incidencia de metástasis pulmonares. Medicina (Buenos Aires) 40: 827-828, 1980
32. Bal de Kier Joffé E, Puricelll L, Sacerdote de Lustig E: Modified adhesion behaviour after in vitro passage of two related murine mammary adenocarcinomas with different metastasizing ability. Inv Met 6: 302-312, 1986
33. Danielpour D, Dart LL, Flanders KC, Roberts AB, Sporn MB: Immunodetection and quantitation of the two forms of TGF-β (TGF-β1 and TGF-β2) secreted by cells in culture. J Cell Phys 138: 79-86, 1989
34. Bradford M: A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principles of protein dye binding. J Biol Chem 260: 11389-11392, 1985
35. Brown PD, Wakefield LM, Levinson AD, Sporn MB: Physico-chemical activation of recombinant latent transforming growth factor-betas 1, 2 and 3. Growth Factors 3: 35-43, 1990
36. Laemmli UK: Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 277: 680-685, 1970
37. Pittman R: Release of plasminogen activator and calcium dependent metalloprotease from cultured symphatic and sensor neurons. Dev Biol 110: 91-101, 1985
38. Alonso DF, Farías EF, Bal de Kier Joffé E: Impairment of fibrinolysis during the growth of two murine mammary adenocarcinomas. Cancer Lett 70: 181-187, 1993
39. Jänkun J, Maher VM, Mc Cormick JJ: Malignant transformation of human fibroblast correlates with increased activity of receptor-bound plasminogen activator. Cancer Res 51: 1221-1226, 1991
40. Mackay AR, Ballin M, Pellina MD, Farina AR, Nason AM, Hartzler JL, Thorgeirsson UP: Effect of phorbol ester and cytokines on MMP and TIMP expression on tumor and normal cell lines. Inv Met 12: 168-184, 1992
41. Sokal RR, Rohlf FJ, Biometry. Freeman, New York, 1995
42. DeLean A, Munson PJ, Rodbard D: Simultaneous analysis of families of sigmoidal curves: application to bioassay, radio-ligand assay and physiological dose-response curves. Am J Physiol 235: E97-E102, 1978
43. Aguirre-Guiso JA, Alonso DF, Farías EF, Gómez DE, Bal de Kier Joffé ED: Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. Eur J Biochem 263: 295-304, 1999
44. Shain KH, Landowski TH, Dalton WS: The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance. Curr Opt Oncol 12: 557-563, 2000
45. Park CC, Bissell MJ, Barcellos-Hoff MH: The influence of the microenvironment on the malignant phenotype. Mol Med Today 6: 324-329, 2000
46. Morton DM, Barrack ER: Modulation of transforming growth factor β1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res 55: 2596-2602, 1995
47. Liu C, Tsao MS, Grisham JW: Transforming growth factors produced by normal and neoplastically transformed rat liver epithelial cells in culture. Cancer Res 48: 850-855, 1988
48. Takiuchi H, Tada T, Li XF, Ogata M, Ikeda T, Fujimoto S, Fujiwara H, Hamaoka T: Particular types of tumor cells have the capacity to convert transforming growth factor β from a latent to an active form. Cancer Res 52: 5641-5646, 1992
49. Fynan TM, Reiss M: Resistance to inhibition of cell growth by TGF-β and its role in oncogenesis. Crit Rev Oncogenesis 4(5): 493-540, 1993
50. Miettinen PJ, Ebner R, Lopez AR, Derynck R: TGF-β induced transdifferentiation of mammary epithelial cells to mesenchymal cells: Involvement of type I receptors. J Cell Biol 127(6): 2021-2036, 1994
51. Moses HL, Yang EY, Pietenpol JA: TGF-β stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 63: 245-247, 1990
52. Mazar AP, Henkin J, Goldfarb RH: The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis 3: 15-32, 1999
53. Sherbet GV, Lakshmi MS: Proteinases and their inhibitors in cancer invasion. In: The Genetics of Cancer - Genes Associated with Cancer Invasion, Metastasis and Cell Proliferation. Academic Press, London, UK, pp 123-143
54. Blasi F: uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways. Immunol Today 18(9): 415-417, 1997
55. Blasi F: Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 15: 105-111, 1993
56. Biliran Jr H, Sheng S: Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Cancer Res 61: 8676-8682, 2001
57. Shi HY, Zhang W, Liang R, Abraham S, Kittrell FS, Medina D, Zhang M: Blocking tumor growth, invasion, and metastasis by maspin in a singeneic breast cancer model. Cancer Res 61: 6945-6951, 2001
58. Stampfer MR, Yaswen P, Alhadeff M, Hosoda J: TGF-β induction of extracellular matrix associated proteins in normal and transformed human mammary epithelial cells in culture is independent of growth effects. J Cell Phys 155: 210-221, 1993
59. Oft M, Heider K-H, Beug H: TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 8: 1243-1252, 1998